{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T10:31:30Z","timestamp":1780914690645,"version":"3.54.1"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:00:00Z","timestamp":1561507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["116030"],"award-info":[{"award-number":["116030"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014132","name":"European Metrology Programme for Innovation and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ctrv.2019.06.004","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T12:17:10Z","timestamp":1561637830000},"page":"57-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Drug-induced gene expression profile changes in relation to intestinal toxicity: State-of-the-art and new approaches"],"prefix":"10.1016","volume":"77","author":[{"given":"Daniela","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terezinha","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyel G.J.","family":"Jennen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieve","family":"Lemmens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos C.S.","family":"Kleinjans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo M.","family":"de Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2019.06.004_b0005","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.clnu.2008.02.005","article-title":"Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction","volume":"27","author":"Crenn","year":"2008","journal-title":"Clin Nutr"},{"key":"10.1016\/j.ctrv.2019.06.004_b0010","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/0192623316644992","article-title":"Identification and evaluation of novel MicroRNA biomarkers in plasma and feces associated with drug-induced intestinal toxicity","volume":"45","author":"Kalabat","year":"2017","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0015","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000107724","article-title":"Intestinal toxicity induced by 5-fluorouracil in pigs: a new preclinical model","volume":"53","author":"Manzano","year":"2007","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ctrv.2019.06.004_b0020","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/mnfr.201200461","article-title":"Role of intestinal microflora in xenobiotic-induced toxicity","volume":"57","author":"Jeong","year":"2013","journal-title":"Mol Nutr Food Res"},{"key":"10.1016\/j.ctrv.2019.06.004_b0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/SPC.0b013e3282f41b71","article-title":"Measuring tools for gastrointestinal toxicity","volume":"2","author":"Butler","year":"2008","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.ctrv.2019.06.004_b0030","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/ncpgasthep0896","article-title":"Drug-induced injury in the gastrointestinal tract: clinical and pathologic considerations","volume":"4","author":"Pusztaszeri","year":"2007","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0035","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ctrv.2011.05.007","article-title":"Biomarkers of regimen-related mucosal injury","volume":"37","author":"Gibson","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2019.06.004_b0040","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1002\/cncr.20163","article-title":"Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis","volume":"100","author":"Rubenstein","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2019.06.004_b0045","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/gut.47.5.632","article-title":"Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans","volume":"47","author":"Keefe","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.ctrv.2019.06.004_b0050","doi-asserted-by":"crossref","first-page":"615","DOI":"10.18388\/abp.2014_1823","article-title":"Plasma citrulline level as a biomarker for cancer therapy induced small bowel mucosal damage","volume":"61","author":"Barza\u0142","year":"2014","journal-title":"Acta Biochim Pol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0055","doi-asserted-by":"crossref","first-page":"e15156","DOI":"10.1371\/journal.pone.0015156","article-title":"Intestinal damage determines the inflammatory response and early complications in patients receiving conditioning for a stem cell transplantation","volume":"5","author":"van der Velden","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2019.06.004_b0060","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/MEG.0000000000000828","article-title":"Short article: small intestinal mucosal injury in patients taking chemotherapeutic agents for solid cancers","volume":"29","author":"Dore","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0065","first-page":"106","article-title":"Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management","volume":"25","author":"Boussios","year":"2012","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0070","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.gtc.2009.03.007","article-title":"Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications","volume":"38","author":"Lanas","year":"2009","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.ctrv.2019.06.004_b0075","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/annonc\/mdp596","article-title":"Citrulline-based assessment score: first choice for measuring and monitoring intestinal failure after high-dose chemotherapy","volume":"21","author":"Herbers","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0080","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.bmt.1704863","article-title":"Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplant","volume":"35","author":"Blijlevens","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ctrv.2019.06.004_b0085","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1200\/JCO.2008.21.6283","article-title":"Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial","volume":"27","author":"Braun","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0090","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cncr.20733","article-title":"Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests","volume":"103","author":"Lutgens","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2019.06.004_b0095","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1177\/0192623311432289","article-title":"Evaluation of potential gastrointestinal biomarkers in a PAK4 inhibitor-treated preclinical toxicity model to address unmonitorable gastrointestinal toxicity","volume":"40","author":"John-Baptiste","year":"2012","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0100","first-page":"2933","article-title":"Biomarkers and non-invasive tests for gastrointestinal mucositis","volume":"25","author":"Kuiken","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2019.06.004_b0105","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2019.06.004_b0110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd.2017.244","article-title":"Impact of a five-dimensional framework on R&D productivity at AstraZeneca","volume":"17","author":"Morgan","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ctrv.2019.06.004_b0115","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nrd4309","article-title":"Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework","volume":"13","author":"Cook","year":"2014","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.ctrv.2019.06.004_b0120","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ebiom.2016.03.006","article-title":"A transcriptomic biomarker to quantify systemic inflammation in sepsis \u2013 a prospective multicenter phase II diagnostic study","volume":"6","author":"Bauer","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ctrv.2019.06.004_b0125","doi-asserted-by":"crossref","first-page":"E10881","DOI":"10.1073\/pnas.1714109114","article-title":"Development and validation of a high-throughput transcriptomic biomarker to address 21st century genetic toxicology needs","volume":"114","author":"Li","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2019.06.004_b0130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12943-019-0945-y","article-title":"Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer","volume":"18","author":"Matsuyama","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ctrv.2019.06.004_b0135","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ehf2.12136","article-title":"Differentiating heart failure phenotypes using sex-specific transcriptomic and proteomic biomarker panels","volume":"4","author":"Toma","year":"2017","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ctrv.2019.06.004_b0140","doi-asserted-by":"crossref","first-page":"e1005457","DOI":"10.1371\/journal.pcbi.1005457","article-title":"Transcriptomics technologies","volume":"13","author":"Lowe","year":"2017","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0145","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1007\/s11427-013-4557-2","article-title":"Transcriptomics: advances and approaches, Science China","volume":"56","author":"Dong","year":"2013","journal-title":"Life Sci"},{"key":"10.1016\/j.ctrv.2019.06.004_b0150","doi-asserted-by":"crossref","first-page":"15216","DOI":"10.3748\/wjg.v20.i41.15216","article-title":"Heterogeneity across the murine small and large intestine","volume":"20","author":"Bowcutt","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006958","article-title":"Intestinal microbiota regulate xenobiotic metabolism in the liver","volume":"4","author":"Bjorkholm","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2019.06.004_b0160","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bbrc.2011.08.094","article-title":"Role of metabolism by the human intestinal microflora in arbutin-induced cytotoxicity in HepG2 cell cultures","volume":"413","author":"Khanal","year":"2011","journal-title":"Biochem Bioph Res Co"},{"key":"10.1016\/j.ctrv.2019.06.004_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2008.07.009","article-title":"The gastrointestinal microbiota as a site for the biotransformation of drugs","volume":"363","author":"Sousa","year":"2008","journal-title":"Int J Pharmaceut"},{"key":"10.1016\/j.ctrv.2019.06.004_b0170","doi-asserted-by":"crossref","first-page":"14728","DOI":"10.1073\/pnas.0904489106","article-title":"Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism","volume":"106","author":"Clayton","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2019.06.004_b0175","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.phrs.2018.04.009","article-title":"Microbiome-mediated bile acid modification: role in intestinal drug absorption and metabolism","volume":"133","author":"Enright","year":"2018","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ctrv.2019.06.004_b0180","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41522-017-0034-1","article-title":"Human microbiome signatures of differential colorectal cancer drug metabolism","volume":"3","author":"Guthrie","year":"2017","journal-title":"NPJ Biofilms Microbiomes"},{"key":"10.1016\/j.ctrv.2019.06.004_b0185","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1021\/acschemneuro.7b00295","article-title":"Emerging data strengthens the argument that the microbiome is the fifth horseman of the drug discovery apocalypse","volume":"8","author":"Lindsley","year":"2017","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.ctrv.2019.06.004_b0190","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1124\/dmd.117.079905","article-title":"Physiological regulation of drug metabolism and transport: pregnancy microbiome, inflammation, infection, and fasting","volume":"46","author":"Morgan","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ctrv.2019.06.004_b0195","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.trsl.2016.08.002","article-title":"Gut microbiome interactions with drug metabolism, efficacy, and toxicity","volume":"179","author":"Wilson","year":"2017","journal-title":"Transl Res"},{"key":"10.1016\/j.ctrv.2019.06.004_b0200","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1021\/acsinfecdis.7b00166","article-title":"Transformation of the anticancer drug doxorubicin in the human gut microbiome","volume":"4","author":"Yan","year":"2018","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.ctrv.2019.06.004_b0205","doi-asserted-by":"crossref","first-page":"e31808","DOI":"10.1371\/journal.pone.0031808","article-title":"5-Fluorouracil induced intestinal mucositis via nuclear factor-kappaB activation by transcriptomic analysis and in vivo bioluminescence imaging","volume":"7","author":"Chang","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2019.06.004_b0210","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/oxfordjournals.annonc.a057793","article-title":"5-Fluorouracil cardiotoxicity: a critical review","volume":"1","author":"Gradishar","year":"1990","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0215","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/cncr.20162","article-title":"Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients","volume":"100","author":"Sonis","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2019.06.004_b0220","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.3748\/wjg.v20.i14.3751","article-title":"Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation","volume":"20","author":"Lee","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0225","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ctrv.2007.03.001","article-title":"The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs","volume":"33","author":"Logan","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2019.06.004_b0230","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00280-010-1540-5","article-title":"Role of platelet-activating factor in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice","volume":"68","author":"Soares","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0235","first-page":"4602","article-title":"Identification of 5-fluorouracil-inducible target genes using cdna microarray profiling","volume":"63","author":"Maxwell","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.06.004_b0240","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1471-2164-7-68","article-title":"Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer","volume":"7","author":"Xi","year":"2006","journal-title":"BMC Genomics"},{"key":"10.1016\/j.ctrv.2019.06.004_b0245","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1476-4598-5-20","article-title":"Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery","volume":"5","author":"De Angelis","year":"2006","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ctrv.2019.06.004_b0250","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1158\/0008-5472.CAN-05-2693","article-title":"Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer","volume":"66","author":"Boyer","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.06.004_b0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114779","article-title":"MicroRNA profiling in human colon cancer cells during 5-fluorouracil-induced autophagy","volume":"9","author":"Hou","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2019.06.004_b0260","first-page":"5453","article-title":"The relationships between p53-dependent apoptosis, inhibition of proliferation, and 5-fluorouracil-induced histopathology in murine intestinal epithelia","volume":"58","author":"Pritchard","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.06.004_b0265","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00795-013-0055-7","article-title":"Diamine oxidase as a marker of intestinal mucosal injury and the effect of soluble dietary fiber on gastrointestinal tract toxicity after intravenous 5-fluorouracil treatment in rats","volume":"47","author":"Fukudome","year":"2014","journal-title":"Med Mol Morphol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0270","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s10147-015-0791-x","article-title":"Gastrointestinal toxicities of 5-fluorouracil increase the proportion of regulatory T cells in intestinal tract: advantages of alternate-day S-1 administration","volume":"20","author":"Kajiwara","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0275","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2006.07.4187","article-title":"Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan","volume":"25","author":"Del Rio","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0280","first-page":"105","article-title":"Molecular markers of chemotherapy toxicity in colorectal cancer","volume":"7","author":"Braun","year":"2010","journal-title":"Curr Colorectal Cancer Rep"},{"key":"10.1016\/j.ctrv.2019.06.004_b0285","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1186\/s12885-016-2826-8","article-title":"Molecular profile of 5-fluorouracil pathway genes in colorectal carcinoma","volume":"16","author":"Kunicka","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2019.06.004_b0290","doi-asserted-by":"crossref","first-page":"e4133","DOI":"10.7717\/peerj.4133","article-title":"A novel approach for human whole transcriptome analysis based on absolute gene expression of microarray data","volume":"5","author":"Bikel","year":"2017","journal-title":"PeerJ"},{"key":"10.1016\/j.ctrv.2019.06.004_b0295","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.fct.2011.10.038","article-title":"Red meat intake-induced increases in fecal water genotoxicity correlate with pro-carcinogenic gene expression changes in the human colon","volume":"50","author":"Hebels","year":"2012","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0300","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.gdata.2015.08.029","article-title":"Tissue-specific patterns of gene expression in the epithelium and stroma of normal colon in healthy individuals in an aspirin intervention trial","volume":"6","author":"Thomas","year":"2015","journal-title":"Genom Data"},{"key":"10.1016\/j.ctrv.2019.06.004_b0305","doi-asserted-by":"crossref","first-page":"e1004085","DOI":"10.1371\/journal.pcbi.1004085","article-title":"PathVisio 3: an extendable pathway analysis toolbox","volume":"11","author":"Kutmon","year":"2015","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0310","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1126\/science.3263702","article-title":"Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors","volume":"242","author":"Yaish","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2019.06.004_b0315","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.ctrv.2019.06.004_b0320","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/jpet.105.084145","article-title":"Role of tyrosine kinase inhibitors in cancer therapy","volume":"315","author":"Arora","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ctrv.2019.06.004_b0325","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.taap.2014.04.015","article-title":"Erlotinib promotes endoplasmic reticulum stress-mediated injury in the intestinal epithelium","volume":"278","author":"Fan","year":"2014","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0330","unstructured":"Roberts LJ, Marrow JD, Hardman JG, Limbird LE. Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of Gout in \u201cGoodman and Gilman's\u201d the Pharmacological basis of therapeutics; 2001."},{"key":"10.1016\/j.ctrv.2019.06.004_b0335","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/bdrb.10003","article-title":"NSAIDs and developmental toxicity","volume":"68","author":"Tassinari","year":"2003","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0340","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/BF02944348","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) and gastro-intestinal toxicity: current issues","volume":"168","author":"Shah","year":"1999","journal-title":"Irish J Med Sci"},{"key":"10.1016\/j.ctrv.2019.06.004_b0345","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ijc.28381","article-title":"Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH\/HES1 and activating PPARG in colorectal cancer","volume":"134","author":"Moon","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2019.06.004_b0350","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/jpet.107.127720","article-title":"Drug-induced alterations to gene and protein expression in intestinal epithelial cell 6 cells suggest a role for calpains in the gastrointestinal toxicity of nonsteroidal anti-inflammatory agents","volume":"325","author":"Raveendran","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ctrv.2019.06.004_b0355","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/toxsci\/kfs310","article-title":"Multiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategies","volume":"131","author":"Boelsterli","year":"2013","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.ctrv.2019.06.004_b0360","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00535-011-0501-z","article-title":"Small bowel injury induced by selective cyclooxygenase-2 inhibitors: a prospective, double-blind, randomized clinical trial comparing celecoxib and meloxicam","volume":"47","author":"Maehata","year":"2012","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0365","doi-asserted-by":"crossref","unstructured":"Maiden, Thjodleifsson B, Seigal A, Bjarnason II, Scott D, Birgisson S. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol 2007; 5: 1040\u20135.","DOI":"10.1016\/j.cgh.2007.04.031"},{"issue":"Suppl 19","key":"10.1016\/j.ctrv.2019.06.004_b0370","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00535-008-2248-8","article-title":"Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy","volume":"44","author":"Maiden","year":"2009","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0375","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ijc.11215","article-title":"Expression profiling of CC531 colon carcinoma cells reveals similar regulation of beta-catenin target genes by both butyrate and aspirin","volume":"106","author":"Germann","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2019.06.004_b0380","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/07357907.2012.754458","article-title":"Celecoxib downregulates CD133 expression through inhibition of the Wnt signaling pathway in colon cancer cells","volume":"31","author":"Deng","year":"2013","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ctrv.2019.06.004_b0385","first-page":"68","article-title":"The effect of celecoxib and its combination with imatinib on human HT-29 colorectal cancer cells: Involvement of COX-2, Caspase-3, VEGF and NF-kappaB genes expression","volume":"62","author":"Atari-Hajipirloo","year":"2016","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"10.1016\/j.ctrv.2019.06.004_b0390","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/jat.3520","article-title":"Development of an alternative zebrafish model for drug-induced intestinal toxicity","volume":"38","author":"Ryu","year":"2018","journal-title":"J Appl Toxicol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0395","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/1055-9965.EPI-04-0866","article-title":"Celecoxib treatment alters the gene expression profile of normal colonic mucosa","volume":"15","author":"Glebov","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ctrv.2019.06.004_b0400","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/1471-2164-9-374","article-title":"Identification of the transcriptional response of human intestinal mucosa to Lactobacillus plantarum WCFS1 in vivo","volume":"9","author":"Troost","year":"2008","journal-title":"BMC Genom"},{"key":"10.1016\/j.ctrv.2019.06.004_b0405","doi-asserted-by":"crossref","first-page":"e0134406","DOI":"10.1371\/journal.pone.0134406","article-title":"Differential gene expression in colon tissue associated with diet, lifestyle, and related oxidative stress","volume":"10","author":"Slattery","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2019.06.004_b0410","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature07935","article-title":"Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche","volume":"459","author":"Sato","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2019.06.004_b0415","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1021\/acsbiomaterials.6b00699","article-title":"In vitro intestinal and liver models for toxicity testing","volume":"3","author":"Orbach","year":"2017","journal-title":"Acs Biomater Sci Eng"},{"key":"10.1016\/j.ctrv.2019.06.004_b0420","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1053\/j.gastro.2015.12.042","article-title":"Organoid models of human gastrointestinal development and disease","volume":"150","author":"Dedhia","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2019.06.004_b0425","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/ncb3312","article-title":"Organoids as an in vitro model of human development and disease","volume":"18","author":"Fatehullah","year":"2016","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.ctrv.2019.06.004_b0430","doi-asserted-by":"crossref","first-page":"e1228","DOI":"10.1038\/cddis.2014.183","article-title":"Ex vivo culture of intestinal crypt organoids as a model system for assessing cell death induction in intestinal epithelial cells and enteropathy","volume":"5","author":"Grabinger","year":"2014","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ctrv.2019.06.004_b0435","unstructured":"TransQST. Translational quantitative systems toxicology to improve the understanding of the safety of medicines."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737219300829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737219300829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:21:47Z","timestamp":1759656107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737219300829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":87,"alternative-id":["S0305737219300829"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2019.06.004","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced gene expression profile changes in relation to intestinal toxicity: State-of-the-art and new approaches","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2019.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}